Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OBIO vs MNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNOV Captures Overall Composite Edge (50.2 HOLD vs 41.1 SELL), While OBIO Leads 3–2 on Growth & Valuation Pillars

MNOV Overall Winner 6-Pillar Tally: OBIO 3 – 2 MNOV (1 Tie) Matrix Metrics: OBIO 3 – 7 MNOV

As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (50.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin).

  • Growth vs. Quality Trade-Off: MNOV earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. OBIO 41.1/100 SELL) and 0.59β · 38% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs MNOV
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.18β · 88% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 55
RSI-14: 54.9 · SMA20: $6.19 · SMA50: $6.01
MNOV NASDAQ Head-to-Head Winner
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (OBIO 3 – 2 MNOV)

Columns: Metric · OBIO · MNOV
1. Valuation Multiples MNOV
Forward P/E N/M 8.5x
Trailing P/E N/M 8.5x
PEG Ratio N/M N/M
EV / Revenue 17.9x 42.5x
2. Growth & Scale OBIO
Revenue Growth (YoY) -89.4% +12.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M $935,717
Market Cap $550.9M $65.1M
3. Profitability & Quality OBIO
Gross Margin 99.6% 42.2%
Operating Margin -195.4% -1232.2%
Net Profit Margin -182.5% 0.0%
Return on Equity (ROE) -182.3% -24.8%
4. Balance Sheet & Cash Flow MNOV
Cash Generation (TTM) -$64M -$9.1M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $25M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 78.2% (21st %ile) 140.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (3) vs MNOV (7)
Institutional Metric OBIO MNOV Criterion Row Edge
Market Capitalization
Scale
$550.9M $65.1M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio
Valuation
N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY)
Growth
-89.4% +12.4% Higher Growth MNOV
Operating Margin (TTM)
Profitability
-195.4% -1232.2% Higher Margin OBIO
Net Profit Margin
Profitability
-182.5% 0.0% Higher Margin MNOV
Return on Equity (ROE)
Capital Efficiency
-182.3% -24.8% Higher ROE MNOV
52-Week Range Position
Momentum
72% ($3–$8) 3% ($1–$4) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.18β · 88% Vol 0.59β · 38% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
41.1 / 100 (SELL) 50.2 / 100 (HOLD) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
$31M $935,717 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% 42.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.9x EV/Rev N/M PEG · 42.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$9.1M ($25M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +27.38 pp
OBIO: +20.29% · MNOV: -7.09%
3M Horizon OBIO +35.34 pp
OBIO: +20.96% · MNOV: -14.38%
6M Horizon OBIO +68.5 pp
OBIO: +62.07% · MNOV: -6.43%
1Y Horizon OBIO +49.59 pp
OBIO: +41.2% · MNOV: -8.39%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue MNOV Revenue OBIO Op. Margin MNOV Op. Margin Margin Leader
FY2012 N/A $0M N/A -1363.8% MNOV
FY2021 N/A $0M N/A -253.0% MNOV
FY2022 $0M N/A -924.3% N/A OBIO
FY2023 $0M $0M -1866.2% -990.0% MNOV
FY2024 $0M N/A -2437.5% N/A OBIO
FY2025 $30M $0M -154.7% -3242.5% OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO CONSOLIDATION
36d in phase · OBV ACCUMULATION
Current IV 78.2%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $550.9M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs MNOV Key Questions & Quantitative Answers

As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (50.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Growth vs. Quality Trade-Off: MNOV earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. OBIO 41.1/100 SELL) and 0.59β · 38% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). Across the 6-period historical trajectory (FY2012 to FY2025), OBIO cumulative revenue shifted N/A while MNOV shifted N/A. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.

MNOV screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus MNOV (-24.8% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.